Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Liquidia Corp amended Second Amendment to Revenue Interest Financing Agreement with HealthCare Royalty Partners IV, L.P. and HealthCare Royalty Management, LLC valued at Amendment moves $2.5 million from fourth tranche to second tranche, resulting in $10 million total s (effective 2023-06-28).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- HealthCare Royalty Partners IV, L.P. and HealthCare Royalty Management, LLC
- Value
- Amendment moves $2.5 million from fourth tranche to second tranche, resulting in $10 million total s
- Effective
- 2023-06-28
Exact text from the filing
On June 28, 2023, Liquidia Technologies and HCR entered into a Second Amendment to the Financing Agreement (the “Second Amendment”), pursuant to which, HCR will move $2.5 million from the fourth tranche to the second tranche under the Financing Agreement. As a result, HCR will fund a total of $10 million (as the second tranche under the Financing Agreement), which will be used for the upfront payment owed to Pharmosa in connection with the transactions contemplated by the License Agreement.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Liquidia Corp entered into License Agreement with Pharmosa Biopharm Inc. valued at Upfront payment of $10 million; potential development milestone payments up to $30 million; potentia (effective 2023-06-28).
- Action
- entry
- Agreement
- license
- Counterparty
- Pharmosa Biopharm Inc.
- Value
- Upfront payment of $10 million; potential development milestone payments up to $30 million; potentia
- Effective
- 2023-06-28
Exact text from the filing
License Agreement with Pharmosa Biopharm On June 28, 2023, Liquidia Technologies, Inc., a Delaware corporation (the “Liquidia Technologies”) and a wholly owned subsidiary of Liquidia Corporation
View on SEC.gov